Related Research Articles
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in the borough of Manhattan in New York City, founded in 1884 as the New York Cancer Hospital. MSKCC is one of 52 National Cancer Institute–designated Comprehensive Cancer Centers. Memorial Sloan Kettering is affiliated with Cornell University's medical school. Its main campus is located at 1275 York Avenue, between 67th and 68th streets, in Manhattan.
Weill Cornell Medicine, officially the Joan & Sanford I. Weill Medical College of Cornell University, is the biomedical research unit and medical school of Cornell University. Along with the Weill Cornell Graduate School of Medical Sciences, Weill Cornell is located at 1300 York Avenue on the Upper East Side of Manhattan in New York City. The medical school is named for its benefactor, former Citigroup chairman Sanford Weill.
The Tri-Institutional MD-PhD Program is an MD-PhD program based in New York City that was formed by combining earlier MD-PhD programs that had their inceptions in 1972. The current version of the program, which is operated by Weill Cornell Medicine, The Rockefeller University, and the Memorial Sloan-Kettering Cancer Center's Sloan Kettering Institute, was created in 1991. Located in the Upper East Side of New York City, the program is currently directed by Dr. Katharine C. Hsu of the Memorial Sloan-Kettering Cancer Center.
Josep Baselga i Torres, known in Spanish as José Baselga was a Spanish medical oncologist and researcher focused on the development of novel molecular targeted agents, with a special emphasis in breast cancer. Through his career he was associated with the Memorial Sloan Kettering Cancer Center, Vall d'Hebron Institute of Oncology, and the Massachusetts General Hospital in their hematology and oncology divisions. He led the development of the breast cancer treatment Herceptin, a monoclonal antibody, that targets the HER2 protein which is impacted in aggressive breast cancers.
William S. Breitbart, FAPM, is an American psychiatrist in Psychosomatic Medicine, Psycho-oncology, and Palliative Care. He is the Jimmie C Holland Chair in Psychiatric Oncology, and the Chief of the Psychiatry Service, Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, He is a Professor of Clinical Psychiatry at Weill Medical College of Cornell University. He was president of the Academy of Psychosomatic Medicine, and the Editor-in-Chief of Palliative and Supportive Care.
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.
David B. Agus is an American physician and author who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and CEO of USC’s Lawrence J. Ellison Institute for Transformative Medicine. He is also the cofounder of several personalized medicine companies and a contributor to CBS News on health topics.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a Professor of Medicine at the Weill Cornell Medical College. In 1997 he was appointed chair of the Department of Medicine at Sloan-Kettering.
Peter T. Scardino is an American cancer surgeon, researcher, and author expert in genitourinary and urological cancers particularly cancer of the prostate. He is chair of the Department of Surgery at Memorial Sloan Kettering Cancer Center.
James Patrick Allison is an American immunologist and Nobel laureate who holds the position of professor and chair of immunology and executive director of immunotherapy platform at the MD Anderson Cancer Center at the University of Texas.
Kenneth Offit is an American cancer geneticist and oncologist. He is currently Chief of the Clinical Genetics Service and the Robert and Kate Niehaus Chair in Inherited Cancer Genomics at Memorial Sloan Kettering Cancer Center. Offit is also a member of the Program in Cancer Biology and Genetics at the Sloan-Kettering Institute, Professor of Medicine and Healthcare Policy and Research at Weill Cornell Medical College, and a member of both the Board of Scientific Counselors of the National Cancer Institute and the Evaluation of Genomic Applications in Practice and Prevention working group of the U.S. Centers for Disease Control.
Andrew Julian Vickers is a biostatistician and attending research methodologist at Memorial Sloan Kettering Cancer Center. Since 2013, he has also been professor of public health at Weill Cornell Medical College. He is the statistical editor for the peer-reviewed journal European Urology.
Jimmie Coker Holland was a founder of the field of psycho-oncology. In 1977, she worked with two colleagues to establish a full-time psychiatric service at Memorial Sloan Kettering Cancer Center. The program was one of the first of its kind in cancer treatment, and trained its psychologists to specialize in issues specific to people with cancer.
Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.
Jason S. Lewis is a British radiochemist whose work relates to oncologic therapy and diagnosis. His research focus is a molecular imaging-based program focused on radiopharmaceutical development as well as the study of multimodality small- and biomolecule-based agents and their clinical translation. He has worked on the development of small molecules as well as radiolabeled peptides and antibodies probing the overexpression of receptors and antigens on tumors.
Dr. Kathleen M. Foley is an American physician. She was an Attending Neurologist at Memorial Sloan-Kettering Cancer Center in New York City. She worked as a professor of Neurology, Neuroscience, and Clinical Pharmacology at Cornell University Weill Medical College. Foley made contributions toward making palliative care for cancer patients accessible. She headed the country's first pain service in a cancer center at Memorial Sloan-Kettering and was the medical director of the Supportive Care Program. In 1999, she became the director of the Open Society Institute’s Project on Death in America. Additionally, Foley was the Director of the WHO Collaborating Center for Cancer Pain Research and Education at Memorial Sloan-Kettering Cancer Center. She holds the Chair of the Society of Memorial Sloan-Kettering Cancer Center in Pain Research and continues to work with the Open Society Institute as the Medical Director of the International Palliative Care Initiative of the Network Public Health Program of the Research.
Philip W. Kantoff is a medical oncologist. He is the chairman and chief executive officer (CEO) of Convergent Therapeutics. He served as the Chairman of Medicine at Memorial Sloan Kettering Cancer Center between 2015 and 2021. He is best known for his contributions to the impact of DNA abnormalities in prostate cancer and the discovery of therapies for metastatic hormone-sensitive prostate cancer.
Carol L. Brown is the Nicholls-Biondi Chair for Health Equity at Memorial Sloan Kettering Cancer Center and a professor at Weill Cornell Medical College. She is a surgeon known for her work on gynecological cancers.
William Pao is an oncologist and Executive Vice President and Chief Development Officer of Pfizer. He was previously the head of Pharma Research and Early Development (pRED) at Roche and a professor of medicine at the Vanderbilt University Medical Center. He is best known for his work in molecular oncology and cancer genomics.
References
- ↑ Scher, Howard I. (2006). "Chemotherapy for Advanced Prostate Cancer: An Expert Interview With Dr. Howard I. Scher". Medscape (Interview). Retrieved 3 December 2016.
- ↑ "Howard I. Scher M.D.: Executive Profile & Biography - Bloomberg" . Retrieved 3 December 2016.
- ↑ "Deborah Lafer to Wed Dr. Howard I. Scher". The New York Times. 1 January 1989. Retrieved 3 December 2016.
- ↑ "Howard I. Scher - Memorial Sloan Kettering Cancer Center" . Retrieved 3 December 2016.
- ↑ "Howard I. Scher M.D., Leading Clinical Oncology Expert, Joins the Board of Directors of Asterias Biotherapeutics" . Retrieved 3 December 2016.
- ↑ "Michael E. Jung, PhD, Charles Sawyers, MD, and Howard I. Scher, MD, Receive Team Science Award From American Association for Cancer Research - The ASCO Post" . Retrieved 3 December 2016.
- ↑ "Howard Scher, MD - Prostate Cancer Foundation" . Retrieved 3 December 2016.